| ID | Title | Body | Facebook Description | Facebook image | Facebook Title | Facebook Video | Twitter Description | Twitter Image | Twitter Title | Meta tags |
|---|---|---|---|---|---|---|---|---|---|---|
| 16377 | 2020 Therapeutic/Indication Pairing Projects | In 2020, NCATS issued one Therapeutic/Indication Pairing Projects award. The funded preclinical projects are serving as “use cases” to demonstrate the utility of an independent crowdsourcing effort or a computational algorithm to predict new therapeutic uses of an existing drug or biologic. AZD0328 to Treat Traumatic Brain Injury University of Texas Health Science Center Houston Principal Investigators: Pramod K. Dash, Ph.D. (University of Texas Houston) Grant Number: 5-UG3TR002739-02 Traumatic brain injury (TBI) remains a public health concern, the consequences of which can lead to long-lasting disability. Uncontrolled inflammation, which can occur after TBI, profoundly influences neuronal survival and outcome. Here, we propose to test if a pharmaceutical (AZD0328) that has already demonstrated safety during unrelated clinical trials can be repurposed to treat TBI-triggered inflammation, reduce pathophysiology and improve cognitive outcome. Learn more about this project in the NIH RePORTER. | /sites/default/files/socialcard.jpg | 2020 Therapeutic/Indication Pairing Projects | /sites/default/files/socialcard.jpg | 2020 Therapeutic/Indication Pairing Projects | ||||
| 16383 | 2019 Therapeutic/Indication Pairing Projects | In spring and fall 2019, NCATS issued two Therapeutic/Indication Pairing Projects awards. The funded preclinical projects are serving as “use cases” to demonstrate the utility of an independent crowdsourcing effort or a computational algorithm to predict new therapeutic uses of an existing drug or biologic. Network-Based Novel Therapeutics in Colorectal Cancers Preclinical Characterization of Saracatinib for Cystic Fibrosis Therapy Network-Based Novel Therapeutics in Colorectal Cancers University of California, San Diego Principal Investigators: Pradipta Ghosh, M.D., Soumita Das, Ph.D. Grant Number: 1-UG3TR002938-01 The past 5 decades of treating cancer patients has resoundingly concluded that conventional approaches are not enough to cure most cancers because these approaches fail to ‘kill’ stem cells within tumors; these are the cells that escape by evolving and give rise to metastases and treatment-resistant disease. Differentiation therapy, which is aimed at re-activating differentiation programs in those stem cells has been shown to have ‘curative’ power in a certain type of blood cancer (leukemia), but such therapies are yet to emerge in cancers and remains an elusive Holy Grail and a grand challenge of our times. To tackle this challenge, this proposal seeks to repurpose one drug and validate one of the first differentiation therapies in cancers, and do so by using novel mathematical algorithms and a transdisciplinary approach that begins and ends at the patient’s bedside. Learn more about this project in the NIH RePORTER. Preclinical Characterization of Saracatinib for Cystic Fibrosis Therapy Cincinnati Children’s Hospital Medical Center Principal Investigators: Anil Jegga, D.V.M., M.Res., John Paul Clancy, M.D., Anjaparavanda P. Naren, Ph.D. Grant Number: 5-UG3TR002612-02 The pursuit of additional therapeutics for cystic fibrosis (CF) is needed due to several limitations of currently FDA-approved therapies. Our data suggest that src kinase inhibitors have a significant therapeutic benefit in CF primarily by impacting multiple CF pathophysiological processes. Saracatinib or AZD0530, a src kinase inhibitor from AstraZeneca, is well tolerated in humans on chronic administration. We therefore propose to test this asset as a novel CF disease modifying therapy. Learn more about this project in the NIH RePORTER. | /sites/default/files/socialcard.jpg | 2019 Therapeutic/Indication Pairing Projects | /sites/default/files/socialcard.jpg | 2019 Therapeutic/Indication Pairing Projects | ||||
| 16098 | Media Advisory: To Improve Health on Earth, NIH-Funded Tissue Chips Push New Boundaries in Space | The sun rising over the International Space Station and Earth. (NASA)March 2, 2020WHAT: With the help of a Falcon 9 rocket, National Institutes of Health-supported research teams will send tiny, bioengineered models of human organs hurtling toward the International Space Station U.S. National Laboratory (ISS National Lab) at thousands of miles per hour. The launch, which will carry tissue chips modeling heart and gut tissue, is scheduled to take place no sooner than March 6, 2020, from Cape Canaveral, Florida.Tissue chips are miniature, 3-D models of human tissues, such as the lung and liver, designed to mimic functions of the human body and support living human tissues and cells. By studying heart and gut tissue models on the ISS National Lab, researchers hope to learn more about molecular changes in heart tissues exposed to the extreme environment of microgravity and get new insights into immune responses in the intestine that could help improve human health back on Earth.The low-gravity environment on the ISS National Lab presents valuable opportunities for research that are not found on Earth. For example, low-gravity environments can cause changes in the human body that are similar to accelerated disease and aging processes. Because these changes happen relatively quickly, the tissue chips sent to the ISS National Lab allow researchers to model and study — on a much shorter timescale — conditions related to aging and disease that might take years to develop on Earth.Both projects are funded through the Tissue Chips in Space initiative, which is a collaboration among the ISS National Lab and the NIH’s National Center for Advancing Translational Sciences (NCATS) and National Institute of Biomedical Imaging and Bioengineering.WHEN: Launch is scheduled for no sooner than March 6, 2020 at 11:50 p.m. ET; monitor twitter.com/Space_Station for schedule changesWHERE: Cape Canaveral, FloridaNIH SPOKESPEOPLE:Danilo Tagle, Ph.D., Associate Director for Special Initiatives, NCATSLucie Low, Ph.D., Scientific Program Manager, Tissue Chip for Drug Screening, NCATS; NIH-NASA Liaison Point of Contact, HHS-NASA Interagency Agreement CoordinatorTo schedule interviews with NCATS staff, please email ncatsinfo@mail.nih.gov or call 301-435-0888.MORE INFORMATION:For more information on NCATS and its tissue chip program, see —Tissue Chip for Drug ScreeningTissue Chips in SpaceTissue Chip ImagesHIGHLIGHTS:Project Details: Five tissue chip projects have already completed their first flight, but none have included heart or gut tissues.The tissue chip project led by researchers at the University of Washington, Seattle and Johns Hopkins University will compare heart tissue grown on Earth with tissue grown in the low-gravity environment of the ISS National Lab over time to assess visible changes to the tissue as well as changes at the molecular level.The project led by researchers at Emulate, Inc., a biotechnology company, will look at how the cells that line intestines, including immune cells, respond to salmonella bacteria and whether probiotics — such as the bacteria found in yogurt and other foods — protect the gut from infection. These findings could help scientists better understand the impact of low gravity on immune responses, which could lead to new avenues for preventing or treating foodborne infections on Earth.Applying Lessons Learned: Both projects benefited from the tissue chip projects that launched on previous flights. For instance, the gut tissue chip includes a simplified version of a pumping system that flew in May 2019, thereby reducing chances for malfunctions during takeoff and return or while in orbit.Earth-bound Analysis: Both of the projects going up in March have earth-bound counterparts. More analysis will occur once the projects sent to the ISS National Lab have returned to Earth and the projects can be compared. Insights gained will help inform plans for the projects’ second flights. In fact, although data analysis is ongoing for the five projects that returned from their trip to the ISS National Lab last year, findings have already led to hardware advances for current projects and to fine-tuning hypotheses and research plans for projects that will return to the ISS National Lab.Technology Development: NCATS and partners from academia, industry and other federal agencies are working to develop tissue chips as predictable and useful models for testing the safety and effectiveness of candidate drugs, vaccines or biologic agents in humans. In addition to offering important biomedical insights, the Tissue Chips in Space initiative is accelerating technological innovation.About the National Center for Advancing Translational Sciences (NCATS): NCATS conducts and supports research on the science and operation of translation — the process by which interventions to improve health are developed and implemented — to allow more treatments to get to more patients more quickly. For more information about NCATS, visit ncats.nih.gov.About the National Institute of Biomedical Imaging and Bioengineering (NIBIB): NIBIB’s mission is to improve health by leading the development and accelerating the application of biomedical technologies. The Institute is committed to integrating engineering and physical sciences with biology and medicine to advance our understanding of disease and its prevention, detection, diagnosis, and treatment. NIBIB supports emerging technology research and development within its internal laboratories and through grants, collaborations, and training. More information is available at the NIBIB website: www.nibib.nih.gov.About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov. | Studying tissue chips in microgravity could produce new insights to improve health on Earth. | /sites/default/files/ISS_Rising_Sun_medium_0.jpg | To Improve Health on Earth, NIH-Funded Tissue Chips Head Into Space | Studying tissue chips in microgravity could produce new insights to improve health on Earth. | /sites/default/files/ISS_Rising_Sun_medium_1.jpg | To Improve Health on Earth, NIH-Funded Tissue Chips Head Into Space | ||
| 16059 | NIH, Tuskegee Researchers Develop Potential New Type of Immunotherapy Across Cancers and Many Other Diseases | A model shows how a small protein, or peptide, called RP-182 (shown in red) is nestled inside a receptor, CD206, in two specific locations (shown in magenta and cyan). This alters the receptor’s shape and activates the receptor. (Jaynes et al., Sci. Transl. Med. 12 (2020): eaax6337)February 26, 2020In reprogramming immune cells to fight tumors, scientists take a page from an ancient playbookTumors can co-opt the body’s immune defenses to evade detection and boost cancer growth. Now, scientists at the National Institutes of Health (NIH) and Tuskegee University in Alabama suggest a potential new therapeutic strategy that employs the immune system against cancer. The team — led by researchers from NIH’s NCATS and National Cancer Institute (NCI) and the College of Agriculture, Environment and Nutrition Sciences at Tuskegee — has shown in laboratory experiments that a novel type of immune therapy can reprogram immune cells to kill cancer cells and halt tumor growth in several types of cancer. The scientists, who reported their findings in the February 12 issue of Science Translational Medicine, also showed the approach has potential for treating other diseases.In recent years, advances in immunotherapy — which harnesses the body’s immune system to fight disease — have garnered headlines as a potentially powerful tool against cancer. But many cancers don’t respond to immunotherapies, and scientists have sought to develop new and more effective immunotherapy approaches.“The field of immunotherapy holds immense promise and has already changed the cancer treatment landscape in immeasurable ways,” said NCATS Director Christopher P. Austin, M.D. “These new findings point to a potential new strategy for using the immune system against cancer and underscore the value of combining expertise in fields like cancer biology, pharmacology and medicinal chemistry in a collaborative effort to move a basic science observation forward.”The work built on research conducted by biochemist Jesse Jaynes, Ph.D., at Tuskegee University. He was studying immune system–related peptides (small proteins) called host defense peptides, which are produced by immune cells, and their roles in infectious disease. These peptides punch holes in the cell membranes of bacteria, killing the bacteria. They also attract a type of immune cell called tumor-associated macrophages to tissue injury sites — but cancers also attract these macrophages for help escaping the immune system and to help the cancers grow.Jaynes saw commonalities among these peptides in many species, and he and his colleagues suspected certain host defense peptides could have broader effects on activating the immune system, especially in cancers.In the study, the researchers tapped into an ancient part of immune system defenses used by organisms to fend off bacteria, viruses and other foreign invaders. They discovered similarities among peptides that play a role in immune systems across organisms and over millions of years of evolution. This research also suggested that these similarities affected the behavior of immune cells, including tumor-associated macrophages. Macrophages are frequently the first line of defense against infection but, conversely, are also cells subverted by cancers.Jaynes’ group, in collaboration with co-authors Udo Rudloff, M.D., Ph.D., a physician-scientist at NCI, and Juan Marugan, Ph.D., a team leader at NCATS, uncovered a receptor, a docking station called CD206 that one peptide uses to attach to the surface of macrophages.“CD206 was likely an entry point on macrophages during evolution for different invading organisms, like bacteria and viruses,” Jaynes said. The team modified the peptide, creating a synthetic version, RP-182, which could bind more strongly to the CD206 receptor.How the peptide acts and what it doesOne goal of the work was to see if the peptide’s ability to attract macrophages would be useful in fighting cancer. Would it be possible to switch the macrophage’s cancer-promoting behavior back to a normal, antitumor, immune system response?NCATS and NCI scientists conducted a series of studies to find out how CD206 works. They found that when RP-182 binds to CD206, the receptor structure changes, sending new chemical signals to reprogram a type of macrophage, M2, to begin killing — literally eating — cancer cells. The NCI group visualized the structural change under a special microscope, while NCATS scientists detailed how RP-182 attached to the receptor.In tumors treated with RP-182, the researchers found that these reprogrammed M2 macrophages devour tumor cells. RP-182 converts M2 macrophages into another macrophage subtype, M1. They saw an increase in M1 macrophages, which consume bacteria, viruses and cancer cells.The RP-182-receptor interaction also had additional anticancer effects. “In addition to converting the macrophages into cancer killers, we found that when RP-182 attached to and altered the CD206 receptor, this also activated an array of other immune cells that help against the cancer,” Marugan said.When Rudloff and his colleagues at NCI gave RP-182 and chemotherapy or another immune therapy to mice with pancreatic cancer, those mice exhibited fewer signs of the disease. These results suggested the possibility of combining this type of therapy with other treatments, including other immunotherapies. The Tuskegee researchers tested RP-182 in additional animal models of cancer, showing that it was also effective against other cancer types and could have wide applicability.“These kinds of peptides existed 400 million years ago,” said Rudloff. “We’ve connected an evolutionary process to an immune mechanism from which we can make a cancer drug. Our results could have broader implications for developing a new approach to immunotherapy.”RP-182 could work in noncancer-tissue mouse models, too. In a lung fibrosis model, the researchers found it reduced lung damage driven by abnormal macrophage activity, and the animals’ conditions improved.“It’s likely there are other examples like this that could provide exciting templates for new cancer drugs,” Rudloff said. “For our patients, our priority is to further develop RP-182 as a cancer drug and get it into the clinic. That’s still a while away.” | NCATS, National Cancer Institute, and Tuskegee University researchers discovered a novel type of immune therapy that can reprogram immune cells to kill cancer cells and halt tumor growth in several ty | /sites/default/files/FIGURE%201C_900x600_0_0.png | Reprogramming Immune Cells to Fight Tumors | NCATS, National Cancer Institute, and Tuskegee University researchers discovered a novel type of immune therapy that can reprogram immune cells to kill cancer cells and halt tumor growth in several ty | /sites/default/files/FIGURE%201C_900x600_0_1.png | Reprogramming Immune Cells to Fight Tumors | ||
| 16029 | NCATS Rare Diseases 2020 Challenge Detailed Submission Requirements | Submissions for this Challenge are now closed. Submission Period: February 29, 2020–June 15, 2020 Entries must be submitted by email to RDChallenge@nih.gov by 5:00 p.m. Eastern Time on June 15, 2020. Include in your subject line: “RDANR Challenge Entry.” Please follow the instructions below to submit your entry. By submitting a solution, all solvers agree to the Challenge terms and conditions, which are detailed on NCATS’ Challenge Details page. Each entry for this Challenge requires a complete “Submission Package.” The Submission Package includes a Cover Letter, the Communication Vehicle and, when appropriate, participant consent forms. Appropriate types of submissions (communication vehicles) include, but are not limited to, songs, music videos, poems, paintings, dramatic readings, mimes, puppets, posters, comics, animations, photos/collages or names for “rare diseases” as a whole. Use any format you choose from those listed below, provided it supports the type of submission—be as creative and original as possible. Please include the following sections and content in your submission and observe page limits. Cover Letter Submission Title Team Leader: Name, email Team Members: Name, role for each team member Other Information The cover letter must be written in English and observe the page limit (1 page), page dimensions (8.5 x 11 inches), font size (11 point or greater) and margin (1 inch) requirements. In the Cover Letter Describe how your submission provides a solution to the Challenge; that is, how does your entry address the problem? Explain why you selected the type of communication vehicle. Describe the target audience and propose a dissemination plan for the entry to reach as many people as possible. Describe whether any collaborations contributed to producing the final entry and the uniqueness of those collaborations (for example, a patient-researcher team, siblings from different diseases, a rare-common disease team and others). Communication Vehicle Follow all instructions to submit the material. Care should be given to select and attach the appropriate file types and formats. Note the following. Accepted File Types Images: .jpg/.jpeg, .gif, .png Microsoft Office: .doc, .docx, .ppt, .pptx, .xls, .xlsx Adobe PDF: .pdf Text: .txt, .rtf Audio/Video: YouTube link (see below) Videos are limited to two minutes in duration. Entrants must post their video submission to YouTube as an unlisted video and send the link to their video entry, along with the required paperwork, to RDChallenge@nih.gov by the deadline. Participant Consent Forms Consent forms must be included for anyone appearing in a submission entry (such as in a photograph or a video), allowing NCATS to use the individual’s name and likeness. Parental consent is required for anyone appearing in the photograph or video who is under the age of 18 years old. Download the consent form (PDF - 148.68KB). To ensure your submission is not blocked by NIH servers, please keep emails smaller than 10 megabytes. Note: You must not use the logo or official seal of HHS nor the logo of NIH or NCATS in the entries, and entries must not claim federal government endorsement. | Detailed information about submission requirements and instructions for NCATS’ Rare Diseases Are Not Rare! 2020 Challenge. | NCATS Rare Diseases 2020 Challenge Detailed Submission Requirements | Detailed information about submission requirements and instructions for NCATS’ Rare Diseases Are Not Rare! 2020 Challenge. | NCATS Rare Diseases 2020 Challenge Detailed Submission Requirements | ||||
| 16026 | NCATS Rare Diseases Are Not Rare! 2020 Challenge Details | Submissions for this Challenge are now closed. View the winners and honorable mentions.Dates and DeadlinesSubject of the Challenge CompetitionRules for Participating in the ChallengeThe PrizeEvaluation and Winner SelectionSubmission Requirements and InstructionsSummaryImage Credit: Tiina Urv, NCATSThe National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), continues to seek innovative ways to communicate with others and educate people about rare diseases through social media or art. The goal of this Challenge, which is being led by NCATS’ Office of Rare Diseases Research (ORDR), is fourfold: First and foremost, it is to raise awareness for all rare diseases in a collective manner (e.g., drawing attention to common challenges, needs or potential solutions). Second, it is intended to bring attention to the many people with rare diseases. Third, it is to highlight the need for research and the development of new treatments. Finally, through the process of creating an entry, it is highly encouraged to build and foster collaborations across the community.The first “NCATS Rare Diseases Are Not Rare!” Challenge was launched in 2018 to raise awareness about rare diseases through creative means. See a list of the winning teams that were selected in winter 2018. ORDR is re-launching the NCATS Rare Diseases Are Not Rare! Challenge in 2020. You can help us get the word out by competing in our rare disease prize competition!Cash prizes for first, second and third place winners are $3,000, $1,500, and $500, respectively. All winners and five honorable mentions will be posted on the NCATS public website.Evaluation criteria that judges will be asked to address are specified below (see Evaluation Criteria under Basis Upon Which Submissions Will Be Evaluated).Dates and DeadlinesEntries must be submitted by email to RDChallenge@nih.gov by 5:00 p.m. EDT on June 15, 2020.The Challenge Begins: Feb. 29, 2020Submission Period: Feb. 29, 2020–June 15, 2020Judging Period: June 16, 2020–July 16, 2020Winners Announced: Summer 2020For Further InformationContact Alice Chen, M.D., NIH (301-827-2015), or send an email.The IC’s Statutory Authority to Conduct the ChallengeThe general purpose of NCATS is to coordinate and develop resources that leverage basic research in support of translational science and to develop partnerships and work cooperatively to foster synergy in ways that do not create duplication, redundancy, and competition with industry activities (42 USC 287(a)). To fulfill its mission, NCATS supports projects that will transform the translational process so that new treatments and cures for diseases can be delivered to patients faster by understanding the translational process and to create a basis for more science-driven, predictive and effective intervention development for the prevention and treatment of all diseases. NCATS supports rare disease patients and their communities by providing translational research funding, tools and other resources that help address their unique challenges. It is beneficial to all stakeholders for NCATS to optimize the communication tools available to support effective information dissemination and education. NCATS is also conducting this Challenge under the America Creating Opportunities to Meaningfully Promote Excellence in Technology, Education, and Science (COMPETES) Reauthorization Act of 2010, 15 U.S.C. 3719. In line with these authorities, this Challenge will lead to innovative ways to communicate with others and to educate people about rare diseases through social media and/or art.Subject of the Challenge CompetitionRare Diseases Are Not Rare! If you know 10 people, chances are you know someone with a rare disease. There are about 7,000 different rare diseases that affect an estimated 30 million people in the United States. This is more than twice the number of people living with cancer, more than the number of people living with HIV and Alzheimer’s disease combined, and more than the current population of Texas.Some difficulties with rare diseases are that they are hard to recognize, they are often hidden conditions, and most do not currently have ongoing medical research. We are asking you to help us bring attention to rare diseases so that they can gain more medical research interest, thereby improving the lives of people with rare diseases. Science, especially genetic medicine, has moved forward to the point now where treatments are possible—such as gene therapies, 3-D printing (devices, tissues and organs) and new drugs. Everyone deserves a chance at an effective medical treatment—whether for a common disease or a rare one—so let’s get the word out!Here are a few facts to consider:Most rare diseases are genetic (around 80%)—they are caused by changes to a person’s DNA (mutations) usually present at birth. We all have DNA, and we all have mutations—whether they cause a disease or not just depends on where the mutations are and whether they impact our ability to function.Rare diseases also can be due to infections—such as Ebola or, in the United States, to malaria, Chagas’ disease or tuberculosis.Many types of cancer, such as leukemia, lymphoma and brain tumors, are rare diseases.About half of those diagnosed with rare diseases are children.Rare diseases can affect anyone, in any family, anywhere in the world. Sometimes they run in families, but often they occur with no family history.Rare diseases can affect many different organs and disease areas, such as lung diseases (e.g., cystic fibrosis), movement (e.g., muscular dystrophy), the brain (e.g., certain types of autism or cerebral palsy), the blood (e.g., sickle cell anemia) and many others.“Cancer” is actually a collection of hundreds of diseases, even though I t is often referred to by just one easily recognizable word.Many common diseases are actually collections of several different rare diseases that affect people in a similar way. For example, “breast cancer” is actually a collection of several different cancers, some of which are rare.You can help by competing in our rare disease prize competition. Here’s what we’re asking you to do:Find a way to communicate with others and educate people about rare diseases through social media or art. Use any communication vehicle you choose—be as creative and original as possible. Here are examples of appropriate communication vehicles:music videosong (with or without sheet music)dramatic readingpoempaintingmimepostercomicanimationphoto/collagenew name for “rare diseases” as a wholepuppetsEach team or individual may submit only one entry.Rules for Participating in the ChallengeSolvers must be 18 years of age or older and may participate singly or as part of one or more teams. Teams are not limited in the number of members. Each team must designate a captain who must be a U.S. citizen or permanent resident and is responsible for all correspondence regarding this Challenge. Teams may also merge, collaborate, subdivide or otherwise organize themselves and their members as needed to prepare a solution for this Challenge.To be eligible to win a prize under this Challenge, an individual or entity—Shall have complied with all the requirements set forth in this Notice;In the case of a private entity, shall be incorporated in and maintain a primary place of business in the United States, and in the case of an individual, whether participating singly or in a group, shall be a citizen or permanent resident of the United States. However, non-U.S. citizens and non-permanent residents can participate as a member of a team that otherwise satisfies the eligibility criteria. Non-U.S. citizens and non-permanent residents are not eligible to win a monetary prize (in whole or in part). Their participation as part of a winning team, if applicable, may be recognized when the results are announced.May not be a Federal entity or Federal employee acting within the scope of their employment;May not be an employee of HHS (or any component of HHS) acting in their personal capacity;Who is employed by a Federal agency or entity other than HHS (or any component of HHS), should consult with an agency Ethics Official to determine whether the Federal ethics rules will limit or prohibit the acceptance of a prize under this Challenge;May not be a judge of the Challenge, or any other party involved with the design, production, execution, or distribution of the Challenge or the immediate family of such a party (i.e., spouse, parent, step-parent, child, or step-child).Federal grantees may not use Federal funds to develop their Submissions.Federal contractors may not use Federal funds from a contract to develop their Submissions or to fund efforts in support of their Submission.Submissions must not infringe upon any copyright or any other rights of any third party.By participating in this Challenge, each individual (whether competing singly or in a group) and entity agrees to assume any and all risks and waive claims against the Federal government and its related entities (as defined in the COMPETES Act), except in the case of willful misconduct, for any injury, death, damage, or loss of property, revenue, or profits, whether direct, indirect, or consequential, arising from participation in this Challenge, whether the injury, death, damage, or loss arises through negligence or otherwise.Based on the subject matter of the Challenge, the type of work that it will possibly require, as well as an analysis of the likelihood of any claims for death, bodily injury, property damage, or loss potentially resulting from Challenge participation, no individual (whether competing singly or in a group) or entity participating in the Challenge is required to obtain liability insurance or demonstrate financial responsibility in order to participate in this Challenge.By participating in this Challenge, each individual (whether competing singly or in a group) and entity agrees to indemnify the Federal government against third party claims for damages arising from or related to Challenge activities.An individual or entity shall not be deemed ineligible because the individual or entity used Federal facilities or consulted with Federal employees during the Challenge if the facilities and employees are made available to all individuals and entities participating in the Challenge on an equitable basis.By participating in this Challenge, each individual (whether participating singly or in a group) and each entity grants to the NIH an irrevocable, paid-up, royalty-free nonexclusive worldwide license to reproduce, publish, post, link to, share, and display publicly the Submission on the web or elsewhere. Each participant will retain all other intellectual property rights in their Submissions, as applicable.NIH reserves the right, in its sole discretion, to (a) cancel, suspend, or modify the Challenge, and/or (b) not award any prizes if no entries are deemed worthy.Each individual (whether participating singly or in a group) or entity agrees to follow all applicable federal, state, and local laws, regulations, and policies.By participating in this Challenge, each individual (whether participating singly or in a group) warrants that he or she is the sole author or owner of, or has the right to use, any copyrightable works that the Submission comprises, that the works are wholly original with the Solver (or is an improved version of an existing work that the Solver has sufficient rights to use and improve), and that the Submission does not infringe any copyright or any other rights of any third party of which Solver is aware. To receive an award, Solvers will not be required to transfer their intellectual property rights to NIH, but Solvers must grant to the federal government a nonexclusive license to practice their solutions and use the materials that describe them. This license must grant to the United States government a nonexclusive, nontransferable, irrevocable, paid-up, royalty-free license to practice or have practiced for or on behalf of the United States throughout the world any invention made by the Solvers that covers the Submission. In addition, the license must grant to the federal government and others acting on its behalf, a fully paid, nonexclusive, irrevocable, worldwide license in any copyrightable works that the Submission comprises, including the right to reproduce, prepare derivative works, distribute copies to the public, and perform publicly and display publicly said copyrightable works. To participate in the Challenge, each Solver must warrant that there are no legal obstacles to providing the above-referenced nonexclusive licenses of Solver’s rights to the federal government.Each individual (whether participating singly or in a group) and entity participating in this Challenge must comply with all terms and conditions of these rules, and participation in this Challenge constitutes each such participant’s full and unconditional agreement to abide by these rules. Winning is contingent upon fulfilling all requirements herein.By participating in this Challenge, each individual (whether participating singly or in a group) agrees to allow NIH to publicly display (e.g., on websites) solutions.The PrizeThe total prize purse is up to $5,000, awarded as follows:First place: $3,000Second place: $1,500Third place: $500Honorable mentions (5) will be posted on NCATS’ website.NIH reserves the right to cancel, suspend and/or modify this Challenge at any time through amendment to this notice. In addition, NIH reserves the right to not award any prizes if no entries are deemed worthy. The Award Approving Official will be Christopher P. Austin, M.D., NCATS director.Payment of the Prize. Prizes awarded under this competition will be paid by electronic funds transfer and may be subject to Federal income taxes. HHS/NIH will comply with the Internal Revenue Service withholding and reporting requirements, where applicable.Evaluation and Winner SelectionBasis upon Which Winner Will Be Selected. A panel of federal and non-federal judges, with expertise directly relevant to this Challenge, will evaluate the entries based on the criteria listed below and will select the Challenge winners.The percentages assigned to each set of evaluation criteria are guidelines from NCATS to suggest which features are of emphasis and interest to the Center.Only complete submissions will be reviewed.Submission Requirements and InstructionsInstructions for submission: Please format submissions using the application instructions and submit by email to RDChallenge@nih.gov by the submission deadline. Use any format you choose from those listed in the application instructions, provided it supports the type of submission—be as creative and original as possible.Each submission for this Challenge requires a complete “Submission Package.” The Submission Package includes a Cover Letter, the Communication Vehicle and, when appropriate, participant consent forms. Appropriate types of submissions (communication vehicles) include, but are not limited to, songs, music videos, poems, paintings, dramatic readings, mimes, puppets, posters, comics, animations, photos/collages or names for “rare diseases” as a whole.Detailed instructions on submission requirements and process can be found here.Cover Letter (1 page)Describe how your submission provides a solution to the Challenge; that is, how does your entry address the problem?Explain why you selected the type of communication vehicle.Describe the target audience and propose a dissemination plan for the entry to reach as many people as possible.Describe whether any collaborations contributed to producing the final entry and the uniqueness of those collaborations (for example, a patient-researcher team, siblings from different diseases, a rare-common disease team, and others).Communication VehicleFollow the instructions in the Detailed Application Instructions to submit the material. Care should be given to select and upload the appropriate file types and formats. Videos are limited to two minutes’ duration.Note: You must not use the logo or official seal of HHS nor the logo of NIH or NCATS in the entries, and entries must not claim federal government endorsement.Evaluation CriteriaBasis upon Which Submissions Will Be Evaluated. Entries will receive up to 5 points for each of the three criteria below, for a total of up to 15 points per entry. Up to 2 bonus points may be awarded for submissions that are a product of unique collaborations, such as a patient-researcher team, siblings from different diseases, rare-common disease team and others.How creative and original is the entry?To what extent does the entry address rare diseases collectively? Entries focused on a single disease or specific group of rare diseases will be considered nonresponsive and will not be judged.How likely is it that the entry could be an effective communication vehicle that appeals to a broad audience and is easy to disseminate? | Guidelines and resources for NCATS’ 2020 Rare Diseases Are Not Rare! Challenge, which seeks creative approaches to raising awareness about rare diseases. | NCATS Rare Diseases Are Not Rare! 2020 Challenge Details | Guidelines and resources for NCATS’ 2020 Rare Diseases Are Not Rare! Challenge, which seeks creative approaches to raising awareness about rare diseases. | NCATS Rare Diseases Are Not Rare! 2020 Challenge Details | ||||
| 16023 | NCATS Challenges and Prize Competitions Program | NCATS runs Challenges to find new and creative approaches to problems from innovative thinkers. Challenges are a flexible alternative to traditional funding mechanisms, such as contracts and grants. By using Challenges, NCATS can encourage collaborations, stimulate innovative ideas, and engage a diverse array of people from all across the country in developing successful solutions to government needs. Learn more about Challenges. Current Opportunities There are no open Challenges at this time. Expired Opportunities The Bias Detection Tools in Health Care Challenge aimed to improve clinician and patient trust in intelligence and machine learning through bias detection and mitigation tools for clinical decision support. The Challenge closed on March 1, 2023. The LitCoin Pilot Design Challenge sought to spur innovation by rewarding the most creative and effective plans to construct the LitCoin submission platform. The Challenge submission window closed on Oct. 31, 2022. Winners have been announced. The LitCoin Natural Language Processing (NLP) Challenge aimed to advance some of the most promising technology solutions built with knowledge graphs. The Challenge launched on Nov. 9, 2021, and the first phase closed Dec. 23, 2021. Winners have been announced. The 2020 ASPIRE Reduction-to-Practice Challenge aimed to spur the development of a comprehensive integrated platform for translational innovation in pain, opioid use disorder and overdose. Winners have been announced. The 2020 Rare Diseases Are Not Rare! Challenge entrants created a gallery of social media and art submissions, from videos and poems to spoken-word performances and personal stories. Winners and honorable mentions have been announced. The 2018 ASPIRE Design Challenges encouraged innovative and catalytic approaches toward solving the opioid crisis by developing “A Specialized Platform for Innovative Research Exploration” (ASPIRE). The 2018 Rare Diseases Are Not Rare! Challenge received nearly 50 submissions, including posters, videos, and poems from people around the country to help bring attention to rare diseases and encourage interest in medical research. Subscribe to the NCATS Announcements Listserv. | NCATS runs Challenges and prize competitions to find innovative, successful solutions from a broad community of problem solvers across the country. | NCATS Challenges and Prize Competitions Program | NCATS runs Challenges and prize competitions to find innovative, successful solutions from a broad community of problem solvers across the country. | NCATS Challenges and Prize Competitions Program | ||||
| 15969 | Improving Treatment Development Through Translational Science | The infographic below shows the challenges associated with treatment development and how translational science can improve the process. | Improving Treatment Development Through Translational Science | Improving Treatment Development Through Translational Science | ||||||
| 15789 | Clinical Trial Readiness for Rare Diseases, Disorders and Syndromes | tbody { border-bottom-style: solid; border-bottom-color: rgb(128, 128, 128, 0.2); border-bottom-width: 2px; } Clinical trials are critical to developing and evaluating new treatments for rare diseases. Scientists, however, often do not have enough information about the symptoms and biology of rare diseases to design clinical trials. NCATS, working with the Eunice Kennedy Shriver National Institute of Child Health and Human Development, created the Clinical Trial Readiness for Rare Diseases, Disorders and Syndromes grants to address some of the obstacles scientists face. These obstacles include, among other issues, gaps in our understanding of a rare disease’s natural history and a lack of suitable biomarkers or clinical outcome measures. Through these grants, NCATS seeks to facilitate rare disease research by enabling efficient and effective movement of candidate therapies or diagnostics toward clinical trials and to increase their likelihood of success. These grants are modeled after a grant program at the National Institute of Neurological Disorders and Stroke. Contact: Alice Chen Grady, M.D. Current Funding Opportunities Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R03 Clinical Trial Not Allowed) PAR-23-160 · Posted Date: 04/13/2023 Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed) PAR-23-159 · Posted Date: 04/13/2023 Funded Research Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R03 Clinical Trial Not Allowed) Principal Investigator(s) Year Awarded Institution Title Weese-Mayer, Debra Ellyn 2022 Lurie Children's Hospital of Chicago PHOX2B Congenital Central Hypoventilation Syndrome (CCHS) Physiologic Signatures in Readiness for Future Clinical Trials Erkan, Elif 2021 Cincinnati Children's Hospital Medical Center Urinary Lipidomic Profile in FSGS: A Novel Biomarker Wheeler, Anne Caroline; Sadhwani, Anjali 2021 Research Triangle Institute Determining Minimal Clinically Important Differences for Neurodevelopmental Outcome Measures in Angelman Syndrome Dwyer, Andrew Alois 2020 Boston College Identifying Predictors of Reversible Congenital Hypogonadotropic Hypogonadism Nihalani, Deepak 2019 Medical University of South Carolina Clinical Assessment of a Novel Non-Invasive Array for Diagnosing Recurrent Focal and Segmental Glomerulosclerosis Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed) Principal Investigator(s) Year Awarded Institution Title Ahrens-Nicklas, Rebecca Clare 2022 Children's Hospital Of Philadelphia Disease Severity Stratification in Multiple Sulfatase Deficiency Bettegowda, Chetan; Holdhoff, Matthias 2022 Johns Hopkins University Cell-free DNA-Based Analysis for Diagnosis, Monitoring and Optimization of Therapy for Patients with Primary Central Nervous System Lymphomas Ferkol, Thomas W.; Storch, Gregory A. 2022 Washington University Characterizing Respiratory Exacerbations in Primary Ciliary Dyskinesia Gupta, Nishant 2022 University of Cincinnati Menstrual Cycle-Related Symptom Variability as a Prognostic Indicator in Lymphangioleiomyomatosis Ou, Yangming; Comi, Anne M.; Pinto, Anna Lecticia 2022 Boston Children's Hospital Brain MRI to Pre-Symptomatically Predict Seizure Onset for Sturge-Weber Syndrome Rosenfeld, Margaret 2022 Seattle Children's Hospital Clinical Trial Readiness - Primary Ciliary Dyskinesia (CTR-PCD) Saba, Julie D. 2022 University of California, San Francisco Validating Absolute Lymphocyte Count and Plasma Sphingosine-1-Phosphate as Disease Biomarkers of Sphingosine Phosphate Lyase Insufficiency Syndrome in Anticipation of a Pyridoxine Clinical Trial Sisley, Stephanie Renee; Elsea, Sarah H. 2022 Baylor College of Medicine Refining Metrics of Food Behavior in Smith-Magenis Syndrome Spurney, Robert 2022 Duke University A Novel Therapeutic Approach to Treat Focal Segmental Glomerulosclerosis (FSGS) Wilkins, Heather M. 2022 University of Kansas Medical Center Functional Biomarkers for ALS Gartel, Andrei L. 2021 University of Illinois at Chicago Targeting FOXM1 in Chemo-Resistant Monocytic AML Holinstat, Michael Allan 2021 University of Michigan at Ann Arbor Biomarkers for 12-Lipoxygenase Inhibition as a Therapeutic Intervention for Heparin-Induced Thrombocytopenia and Thrombosis (HIT/T) Kartha, Reena V. 2021 University of Minnesota Dose Optimization of Nervonic Acid - a Potential Therapy to Alleviate Disease Progression in Adrenoleukodystrophy Kim, Sarah 2021 University of Florida Optimizing Muscular Dystrophy Clinical Trial Designs Using Modeling and Simulation Li, Jun; Dortch, Richard 2021 Wayne State University MRI Biomarkers of Disease Progression in Inherited Neuropathies Peters, Sarika U. 2021 Vanderbilt University Medical Center Clinical Validation of At-Home Methods of Sleep Assessment in Rett Syndrome Rizzo, William B. 2021 University of Nebraska Medical Center Defining Ichthyosis in Sjogren-Larsson Syndrome for Clinical Trial Preparedness Thangarajh, Mathula 2021 Virginia Commonwealth University PAR-18-953 (ASCOT-DMD) Bickers, David Rinsey 2020 Columbia University Health Sciences Tumor Immune Profiling to Optimize Clinical Trial Readiness in Basal Cell Nevus Syndrome Ghayee, Hans K. 2020 University of Florida Preclinical Evaluation of the Efficacy and Mechanism of Action for an Alkylated Polyamine Analogue Diethylnorspermine in Treating Pheochromocytoma/Paraganglioma Grange, Dorothy Katherine; Nichols, Colin G. 2020 Washington University Clinical Trial Readiness for K Channel Inhibitors in Cantu Syndrome Harris, Peter C.; Lieske, John C. 2020 Mayo Clinic Rochester Facilitating Personalized Medicine of Monogenic Stone Patients by Genetic Characterization Johnson, Nicholas Elwood; Statland, Jeffrey 2020 Virginia Commonwealth University Development and Validation of Clinical Outcome Assessments in LGMD2A Lederman, Howard M.; Lefton-Greif, Maureen A.; Natale, Valerie 2020 Children’s Hospital of Philadelphia Methods to Improve Clinical Trials for A-T Li, Dong 2020 Children’s Hospital of Philadelphia Characterization of Rasopathy Mutations Underlying Lymphatic Anomalies and Preparation for Clinical Development Neul, Jeffrey L. 2020 Vanderbilt University Medical Center Development of a Reliable, Valid and Sensitive Outcome Measure in Rett Syndrome Palmer, Scott M. 2020 Duke University Proof of Concept Treatment Interventions in a Rodent Model of the Rare Disease Bronchiolitis Obliterans Sneag, Darryl 2020 Hospital for Special Surgery Magnetic Resonance and Ultrasound Imaging as Biomarkers for Detection and Monitoring of Parsonage-Turner Syndrome (PTS) Arnold, Steven E. 2019 Massachusetts General Hospital Biomarkers to Enable ASO Prevention Trials in Genetic Prion Disease Carriers Byiers, Breanne J. 2019 University of Minnesota Evaluating the Psychometric Properties of Three Clinical Trial Outcome Measures for Rett Syndrome Caldovic, Ljubica; Ah Mew, Nicholas 2019 Children’s Research Institute Systemic Biomarkers of Brain Injury from Hyperammonemia Lynch, David Robinson 2019 Children’s Hospital of Philadelphia Frataxin Measurement for Clinical Trial Readiness in Friedreich Ataxia Muir, Amanda Brooke; Menard-Katcher, Calies D. 2019 Children’s Hospital of Philadelphia Distensibility and Remodeling as Markers of Therapeutic Response in Eosinophilic Esophagitis Shy, Michael E. 2019 University of Iowa Clinical Trial Readiness for Rare Diseases, Disorders and Syndromes Related Information Read more about the goals of the CTR grants program. Learn about related programs: Rare Diseases Clinical Research Network – The RDCRN supports consortia of medical research centers that work together to investigate groups of related rare diseases. Therapeutics for Rare and Neglected Diseases – The TRND program supports preclinical development of therapeutic candidates intended to treat rare or neglected disorders. | Clinical Trial Readiness for Rare Diseases, Disorders and Syndromes | Clinical Trial Readiness for Rare Diseases, Disorders and Syndromes | ||||||
| 15708 | 2019 CCIA Projects | Translational Research Workforce Training: Leveraging the Veterinary Specialist Genetic and Functional Dissection of Congenital Anomalies of the Brain SPROUT–CTSA Collaborative Telehealth Research Network ICT Tools for Rare Diseases Repurposing Pharmacological Agents for Inherited Mast Cell Disorders of the Gut Unintended Prolonged Opioid Use Instrumenting the Delivery System for a Genomics Research Information Commons Enhancing Infrastructure for Clinical and Translational Research to Address the Opioid Epidemic Coordinated Medical Treatment of Opioid Use Disorder and Infectious Disease Translational Research Workforce Training: Leveraging the Veterinary Specialist University of Wisconsin–Madison Principal Investigator: Lauren A. Trepanier, D.V.M., Ph.D. Grant Number: 1-U01TR002953-01 Collaborating Institutions: University of California, Davis; University of Minnesota; University of Florida Advances in human health rely on valid animal models of disease. Rodent models can answer important questions about disease pathogenesis and test promising therapies, but sometimes fail to predict disease responses seen in humans. Naturally occurring (spontaneous) diseases in companion animals—such as epilepsy, glaucoma, or hemophilia—can advance our understanding of similar diseases in human patients. This project will support the professional development of veterinary specialists with expertise in these animal diseases to become clinician-scientists who can be productive contributors to interdisciplinary research teams that can address human health problems from multiple perspectives. Learn more about this project in the NIH RePORTER. Genetic and Functional Dissection of Congenital Anomalies of the Brain The University of North Carolina at Chapel Hill Principal Investigator: Neeta L. Vora, M.D. Grant Number: 1-R21TR002770-01 Collaborating Institution: Duke University Human brain development remains an incompletely understood process, yet congenital brain abnormalities affect approximately three in 1,000 pregnancies and more than 2,000 newborns annually in the United States. Diagnostic tools—such as fetal magnetic resonance imaging, prenatal ultrasound and prenatal gene sequencing—are capable of increasing our understanding of the human brain. By intersecting human prenatal gene sequencing in pregnancies affected by congenital brain abnormalities, bioinformatics filters to identify novel candidate genes, and functional modeling in zebrafish, we aim to develop a workflow that can be adapted broadly across organ systems to investigate of novel candidate genes. Learn more about this project in the NIH RePORTER. SPROUT–CTSA Collaborative Telehealth Research Network Medical University of South Carolina Principal Investigator: Steven D. McSwain, M.D. Grant Number: 1-U01TR002626-01 Collaborating Institutions: Children’s Hospital of Philadelphia, Mercy Health, American Academy of Pediatrics, University of Colorado Denver Because of the rapid evolution of telehealth and the resulting variety and complexity of different telehealth practices across the country, conducting quality research into the impact of telehealth services on health care costs, quality and access historically has been a challenge. The SPROUT (Supporting Pediatric Research on Outcomes and Utilization of Telehealth) Collaborative was established in collaboration with the American Academy of Pediatrics to rigorously evaluate pediatric telehealth services. The SPROUT–Clinical and Translational Science Award (CTSA) Collaborative Telehealth Research Network will enhance the existing infrastructure and expertise of SPROUT with the established research resources of the national CTSA Consortium to develop, iteratively test and enhance, and disseminate an innovative model for clinical and translational telehealth research. Learn more about this project in the NIH RePORTER. ICT Tools for Rare Diseases Research Triangle Institute Principal Investigator: Ty A. Ridenour, Ph.D. Grant Number: 1-R21TR002402-01A1 Collaborating Institution: Harvard University Treatment efficacy and effectiveness studies nearly always use randomized controlled trials, which require large samples and funding pools and are therefore not feasible for numerous rare diseases. This R21 proposal for an NCATS Exploratory CTSA Collaborative Innovation Award is to create tools to assist researchers of rare diseases in conducting idiographic clinical trials (ICTs), which use subject-as-own-control experimental designs, time series data and hierarchical modeling that is tailored for small samples, including N=1. This approach to conducting clinical trials requires far fewer resources than randomized controlled trials; enables rigorous small-sample clinical trials; and allows efficacy testing for rare diseases, hard-to-reach locales and underrepresented peoples. Learn more about this project in the NIH RePORTER. Repurposing Pharmacological Agents for Inherited Mast Cell Disorders of the Gut University of Pittsburgh Principal Investigator: Yelizaveta Konnikova, M.D., Ph.D. Grant Number: 1-R21TR002639-01A1 Collaborating Institutions: University of Florida, Harvard University, The University of New Mexico In this study, mast cells (MC) from patients with hereditary alpha tryptasemia (HAT), a disorder in which multiple copies of the TPSAB1 gene correlate with elevated serum tryptase, are used to study the effect of MC phenotype and function on the chronic inflammatory effects in the gut. This knowledge will be utilized to develop new therapeutic uses for existing drugs that target MC functional pathways. The purpose of this multicenter Clinical and Translational Sciences Institute supplement is to use current state-of-the-art techniques to explain differences in functional MC and inflammatory gut tissue in patients with HAT compared with MC in control patients (patients with inflammatory bowel disease in remission and systemic mastocytosis patients). Learn more about this project in the NIH RePORTER. Unintended Prolonged Opioid Use Mayo Clinic, Rochester Principal Investigator: W. Michael Hooten, M.D. Grant Number: 1-U01TR002743-01 Collaborating Institutions: University of Minnesota, University of Michigan, Yale University Intentional short-term opioid use is emerging as a previously underrecognized segue to unintended prolonged opioid use (UPOU). Clinical strategies aimed at preventing UPOU in health care settings are lacking, due in part to an absence of information about how this poorly understood clinical phenomenon develops. A recently developed conceptual framework to explain UPOU includes patient characteristics, practice environment characteristics and opioid prescriber characteristics that interact to either facilitate or impede UPOU. In this application, four CTSA hubs will explore the potential of a secure mobile personal health platform to identify incident cases of UPOU and to prospectively recruit patients and opioid prescribers for assessments that will be used to evaluate the conceptual framework of UPOU. Learn more about this project in the NIH RePORTER. Instrumenting the Delivery System for a Genomics Research Information Commons Boston Children’s Hospital Principal Investigator: Kenneth L. Mandl, M.D. Grant Number: 1-U01TR002623-01A1 Collaborating Institutions: Harvard University, Children’s Hospital of Philadelphia, Cincinnati Children’s Hospital, University of Pittsburgh, Washington University in St. Louis A patient’s genetic variant must be contextualized against a population-based reference and detailed phenotype to assess its pathogenicity and impact on prognosis, based on the care trajectories and outcomes of other patients with the variant, or similar variants, of a particular gene. However, CTSA researchers do not have ready access to a definitive and representative reference dataset linking the genome to diagnosis, clinical progression, therapeutic response and precision-adjusted laboratory reference ranges. We will facilitate a CTSA-wide, federated Genomics Information Commons, underpinned by coordinated, local, broadly consented biobanking initiatives. The goal is rapid identification and analysis of representative cohorts, made possible by a federated information technology infrastructure, with advanced phenotype and genotype query capability. Learn more about this project in the NIH RePORTER. Enhancing Infrastructure for Clinical and Translational Research to Address the Opioid Epidemic Medical University of South Carolina Principal Investigator: Leslie A. Lenert, M.D. Grant Number: 1-U01TR002628-01A1 Collaborating Institutions: University of California, San Diego; University of Kentucky; Dartmouth College Patients presenting with opioid-related overdose to hospital emergency departments represent a high-risk group for morbidity and mortality and a potential target for interventions to combat the opioid epidemic. This proposal aims to develop a feasible and effective interinstitutional research database and network focused on these patients. These tools will inform point-of-care service delivery, as well as enhance nationwide prevention and treatment interventions. Learn more about this project in the NIH RePORTER. Coordinated Medical Treatment of Opioid Use Disorder and Infectious Disease Yale University Principal Investigator: Sandra Ann Springer, M.D. Grant Number: 1-U01TR002763-01 Collaborating Institutions: Columbia University, Medical University of South Carolina Opioid use disorders (OUD) have significantly increased in the United States and are associated with a rise in invasive bacterial infections and new epidemics of HIV and hepatitis C virus. Infectious disease (ID) specialists and hospitalists are a critical and logical resource to build capacity and increase access to medication treatment for this population of patients with OUD and infections. We will conduct a randomized controlled trial of a new model of care in which OUD is managed by ID specialists and hospitalists, concurrent with management of the OUD-related infections using long-acting injectable buprenorphine, with the hypothesis that this model of care will increase successful referral and transition to community-based outpatient medication treatment for OUD, reducing opioid use and related morbidity. Learn more about this project in the NIH RePORTER. | 2019 CCIA Projects | 2019 CCIA Projects |
Last updated on